WARREN, N.J., Oct. 1, 2024 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the FDA has accepted for filing the New Drug Application (NDA) of sepiapterin for the treatment of pediatric and adult patients living with…Original Article
You may also like
UroGen Submits Completed UGN-102 NDA Seeking Approval...
FDA Accepts LEO Pharma’s Filing of Delgocitinib...
Iterum Therapeutics Provides Update on FDA Advisory...
AbbVie Submits Biologics License Application to the...
Stealth BioTherapeutics Announces Positive Vote from...
UroGen Announces FDA Acceptance of its New Drug...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.